Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma.


Journal

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
ISSN: 1530-0285
Titre abrégé: Mod Pathol
Pays: United States
ID NLM: 8806605

Informations de publication

Date de publication:
02 2022
Historique:
received: 26 05 2021
accepted: 27 09 2021
revised: 17 09 2021
pubmed: 16 10 2021
medline: 5 4 2022
entrez: 15 10 2021
Statut: ppublish

Résumé

Squamous cell carcinomas of the lower female genital tract may be human papillomavirus-associated or independent. We studied the HPV status, mutational repertoire, histology, and clinical data of 28 samples from 26 patients, 65% with a vulvar primary and 35% with a vaginal primary. These represented invasive vulvovaginal squamous cell carcinomas that underwent clinical tumor-normal targeted massively parallel sequencing analysis. HPV status was determined using the HPV high-risk RNA ISH assay and/or by MSK-IMPACT. Eleven patients had HPV-associated squamous cell carcinoma (four vulvar and seven vaginal) and 15 patients had HPV-independent SqCC (13 vulvar and 2 vaginal). Well-differentiated squamous cell carcinomas were always HPV-independent. HPV-independent moderately and poorly differentiated carcinomas frequently had alterations in the NOTCH signaling pathway (6/7), which were also associated with increased tumor budding (P: 0.002). HPV-associated vulvovaginal squamous cell carcinoma had PIK3CA activating mutations (7/11, 64%) as the most common genomic event, while TERT gene alterations, mainly TERT promoter mutations (14/15 cases, 93%) featured significantly in HPV-independent carcinomas. Other common abnormalities in HPV-independent tumors were TP53 mutations (13/15, 87%), CDKN2A alterations (10/15, 67%), and NOTCH1 and FAT1 mutations (7/15, 47% each). A subset of both HPV-associated and -independent tumors had NOTCH pathway alterations (6/11, 55% and 10/15, 67% respectively), but different genes in this pathway were altered in these tumors. In summary, TERT, TP53, CDKN2A, and NOTCH1 gene alterations strongly point away from an HPV-driven process (odds ratios: 0.01, 0.07, 0, and 0, respectively with p values < 0.02 for all four genes), while PIK3CA activating mutations without the other mutations strongly favors an HPV-driven tumor (odds ratio: 10.12, p value: 0.016). HPV-independent carcinomas are more likely to be moderately-poorly differentiated with intermediate to high tumor cell budding. Cancer cell fraction analysis of HPV-independent squamous carcinomas suggests that TERT and/or NOTCH1 alterations along with TP53 alterations can be the initiating event in these tumors.

Identifiants

pubmed: 34650187
doi: 10.1038/s41379-021-00942-3
pii: S0893-3952(22)00339-8
pmc: PMC9450957
mid: NIHMS1832798
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

274-282

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD088590
Pays : United States

Informations de copyright

© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

Références

Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).
pubmed: 31912902 doi: 10.3322/caac.21590
Han, M. R. et al. Mutational signatures and chromosome alteration profiles of squamous cell carcinomas of the vulva. Exp. Mol. Med. 50, e442 (2018).
pubmed: 29422544 pmcid: 5903820 doi: 10.1038/emm.2017.265
Del Pino, M., Rodriguez-Carunchio, L. & Ordi, J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology 62, 161–175 (2013).
pubmed: 23190170 doi: 10.1111/his.12034
Clancy, A. A., Spaans, J. N. & Weberpals, J. I. The forgotten woman’s cancer: Vulvar Squamous Cell Carcinoma (VSCC) and a targeted approach to therapy. Ann. Oncol. 27, 1696–1705 (2016).
pubmed: 27329249 doi: 10.1093/annonc/mdw242
Trietsch, M. D., Nooij, L. S., Gaarenstroom, K. N. & van Poelgeest, M. I. Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: a review of the current literature. Gynecol. Oncol. 136, 143–157 (2015).
pubmed: 25448458 doi: 10.1016/j.ygyno.2014.11.002
Hoang, L. N., Park, K. J., Soslow, R. A. & Murali, R. Squamous precursor lesions of the vulva: current classification and diagnostic challenges. Pathology 48, 291–302 (2016).
pubmed: 27113549 doi: 10.1016/j.pathol.2016.02.015
Cormio, G. et al. Groin recurrence in carcinoma of the vulva: management and outcome. Eur. J. Cancer Care 19, 302–307 (2010).
doi: 10.1111/j.1365-2354.2008.01011.x
Akbari, A. et al. Differentiated exophytic vulvar intraepithelial lesion: clinicopathologic and molecular analysis documenting its relationship with verrucous carcinoma of the vulva. Mod Pathol 33, 2011–2018 (2020).
pubmed: 32427961 doi: 10.1038/s41379-020-0573-5
Nascimento, A. F. et al. Vulvar acanthosis with altered differentiation: a precursor to verrucous carcinoma? Am. J. Surg. Pathol. 28, 638–643 (2004).
pubmed: 15105653 doi: 10.1097/00000478-200405000-00012
Kurman R. J., C. M, Herrington C. S. WHO Classification of Tumours of Female Reproductive Organs. 4th edn, Vol. 6th (Inter-national Agency for Research on Cancer: Lyon, 2014).
Zaino, R. J. et al. Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. Cancer 69, 1750–1758 (1992).
pubmed: 1551060 doi: 10.1002/1097-0142(19920401)69:7<1750::AID-CNCR2820690717>3.0.CO;2-S
Xu, B. et al. The prognostic role of histologic grade, worst pattern of invasion, and tumor budding in early oral tongue squamous cell carcinoma: a comparative study. Virchows Arch. 479, 597–606 (2021).
pubmed: 33661329 doi: 10.1007/s00428-021-03063-z
Lugli, A. et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod. Pathol. 30, 1299–1311 (2017).
pubmed: 28548122 doi: 10.1038/modpathol.2017.46
Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).
pubmed: 27270079 pmcid: 5027494 doi: 10.1093/nar/gkw520
Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396–398 (2014).
pubmed: 24633410 pmcid: 4864026 doi: 10.1038/nmeth.2883
Darragh, T. M. et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch. Pathol. Lab. Med. 136, 1266–1297 (2012).
pubmed: 22742517 doi: 10.5858/arpa.LGT200570
Mills, A. M., Dirks, D. C., Poulter, M. D., Mills, S. E. & Stoler, M. H. HR-HPV E6/E7 mRNA in situ hybridization: validation against PCR, DNA in situ hybridization, and p16 immunohistochemistry in 102 samples of cervical, vulvar, anal, and head and neck neoplasia. Am. J. Surg. Pathol. 41, 607–615 (2017).
pubmed: 28403015 doi: 10.1097/PAS.0000000000000800
Bowman, A. et al. Identification of viral integration sites in cancer genomes using unmapped reads in targeted next-generation sequencing data. J. Mol. Diagn. 963-964 (Elsevier Science Inc, New York, NY, USA).
Williams, E. A. et al. Vulvar squamous cell carcinoma: comprehensive genomic profiling of HPV+ versus HPV- forms reveals distinct sets of potentially actionable molecular targets. JCO Precis. Oncol. 4, 647–661 (2020).
doi: 10.1200/PO.19.00406
Watkins, J. C. et al. Differentiated exophytic vulvar intraepithelial lesions are genetically distinct from keratinizing squamous cell carcinomas and contain mutations in PIK3CA. Mod. Pathol. 30, 448–458 (2017).
pubmed: 27834349 doi: 10.1038/modpathol.2016.187
Mulvany, N. J. & Allen, D. G. Differentiated intraepithelial neoplasia of the vulva. Int. J. Gynecol. Pathol. 27, 125–135 (2008).
pubmed: 18156987 doi: 10.1097/pgp.0b0318134ea34
van de Nieuwenhof, H. P. et al. The etiologic role of HPV in vulvar squamous cell carcinoma fine tuned. Cancer Epidemiol. Biomark. Prev. 18, 2061–2067 (2009).
doi: 10.1158/1055-9965.EPI-09-0209
van der Avoort, I. A. et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. Int. J. Gynecol. Pathol. 25, 22–29 (2006).
pubmed: 16306780 doi: 10.1097/01.pgp.0000177646.38266.6a
Pors, J. et al. Targeted molecular sequencing of recurrent and multifocal non-HPV-associated squamous cell carcinoma of the vulva. Int. J. Gynecol. Pathol. 40, 391–399 (2021).
pubmed: 33323855 doi: 10.1097/PGP.0000000000000742
Tessier-Cloutier, B. et al. Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome. Mod. Pathol. 34, 508–518 (2021).
pubmed: 32792599 doi: 10.1038/s41379-020-00651-3
Zieba, S. et al. Somatic mutation profiling of vulvar cancer: exploring therapeutic targets. Gynecol. Oncol. 150, 552–561 (2018).
pubmed: 29980281 doi: 10.1016/j.ygyno.2018.06.026
Nooij, L. S. et al. Genomic characterization of vulvar (pre)cancers identifies distinct molecular subtypes with prognostic significance. Clin. Cancer Res. 23, 6781–6789 (2017).
pubmed: 28899974 doi: 10.1158/1078-0432.CCR-17-1302
Weberpals, J. I. et al. Vulvar squamous cell carcinoma (VSCC) as two diseases: hpv status identifies distinct mutational profiles including oncogenic fibroblast growth factor receptor 3. Clin. Cancer Res. 23, 4501–4510 (2017).
pubmed: 28377483 doi: 10.1158/1078-0432.CCR-16-3230
Zieba, S. et al. Somatic mutation profiling in premalignant lesions of vulvar squamous cell carcinoma. Int. J. Mol. Sci. 21, 4880 (2020).
pmcid: 7402303 doi: 10.3390/ijms21144880
Kunjoonju, J. P., Raitanen, M., Grenman, S., Tiwari, N. & Worsham, M. J. Identification of individual genes altered in squamous cell carcinoma of the vulva. Genes Chromosomes Cancer 44, 185–193 (2005).
pubmed: 16001430 doi: 10.1002/gcc.20230
Trietsch, M. D. et al. CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. Gynecol. Oncol. 135, 149–155 (2014).
pubmed: 25072932 doi: 10.1016/j.ygyno.2014.07.094
Carreras-Dieguez, N. et al. Molecular landscape of vulvar squamous cell carcinoma. Int. J. Mol. Sci. 22, 7069 (2021).
pubmed: 34209172 pmcid: 8269046 doi: 10.3390/ijms22137069
Pinto, A. P. et al. Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma. Gynecol. Oncol. 92, 856–865 (2004).
pubmed: 14984953 doi: 10.1016/j.ygyno.2003.11.052
Alonso, I. et al. Does human papillomavirus infection imply a different prognosis in vulvar squamous cell carcinoma? Gynecol. Oncol. 122, 509–514 (2011).
pubmed: 21652058 doi: 10.1016/j.ygyno.2011.05.016
McAlpine, J. N. et al. Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study. Histopathology 71, 238–246 (2017).
pubmed: 28257152 doi: 10.1111/his.13205
Allo, G. et al. HPV-independent vulvar squamous cell carcinoma is associated with significantly worse prognosis compared with HPV-associated tumors. Int. J. Gynecol. Pathol. 39, 391–399 (2020).
pubmed: 31274700 doi: 10.1097/PGP.0000000000000620
Kortekaas, K. E. et al. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Gynecol. Oncol. 159, 649–656 (2020).
pubmed: 32972785 doi: 10.1016/j.ygyno.2020.09.024
Crook, T., Vousden, K. H. & Tidy, J. A. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67, 547–556 (1991).
pubmed: 1657399 doi: 10.1016/0092-8674(91)90529-8
Yim, E. K. & Park, J. S. The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis. Cancer Res. Treat. 37, 319–324 (2005).
pubmed: 19956366 pmcid: 2785934 doi: 10.4143/crt.2005.37.6.319
Agoff, S. N. et al. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod. Pathol. 16, 665–673 (2003).
pubmed: 12861062 doi: 10.1097/01.MP.0000077518.78046.0C
Santos, M. et al. p16 overexpression identifies HPV-positive vulvar squamous cell carcinomas. Am. J. Surg. Pathol. 30, 1347–1356 (2006).
pubmed: 17063073 doi: 10.1097/01.pas.0000213251.82940.bf
GEIßLER, C. et al. The role of p16 expression as a predictive marker in HPV-positive oral SCCHN–a retrospective single-center study. Anticancer Res. 33, 913–916 (2013).
pubmed: 23482761
Rakislova, N. et al. Histological characteristics of HPV-associated and -independent squamous cell carcinomas of the vulva: a study of 1594 cases. Int. J. Cancer 141, 2517–2527 (2017).
pubmed: 28815579 doi: 10.1002/ijc.31006
Pilotti, S. et al. Papillomavirus, p53 alteration, and primary carcinoma of the vulva. Diagn Mol Pathol 4, 239–248 (1995).
pubmed: 8634779 doi: 10.1097/00019606-199512000-00003
Soufir, N. et al. Inactivation of the CDKN2A and the p53 tumour suppressor genes in external genital carcinomas and their precursors. Br. J. Dermatol. 156, 448–453 (2007).
pubmed: 17300232 doi: 10.1111/j.1365-2133.2006.07604.x
Panczyszyn, A., Boniewska-Bernacka, E. & Glab, G. Telomeres and telomerase during human papillomavirus-induced carcinogenesis. Mol. Diagn. Ther. 22, 421–430 (2018).
pubmed: 29777397 pmcid: 6061425 doi: 10.1007/s40291-018-0336-x
Branca, M. et al. Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus, virus persistence, or disease outcome in cervical cancer. Diagn. Cytopathol. 34, 739–748 (2006).
pubmed: 17041957 doi: 10.1002/dc.20554
Miller, J. et al. HPV16 E7 protein and hTERT proteins defective for telomere maintenance cooperate to immortalize human keratinocytes. PLoS Pathog. 9, e1003284 (2013).
pubmed: 23592995 pmcid: 3617164 doi: 10.1371/journal.ppat.1003284
Pinto, A. P. et al. Differentiated vulvar intraepithelial neoplasia contains Tp53 mutations and is genetically linked to vulvar squamous cell carcinoma. Mod. Pathol. 23, 404–412 (2010).
pubmed: 20062014 doi: 10.1038/modpathol.2009.179
Choschzick, M. et al. Role of TP53 mutations in vulvar carcinomas. Int. J. Gynecol. Pathol. 30, 497–504 (2011).
pubmed: 21804386 doi: 10.1097/PGP.0b013e3182184c7a
Fan, Y. et al. Telomerase expression by aberrant methylation of the TERT promoter in melanoma arising in giant congenital Nevi. J. Invest. Dermatol. 136, 339–342 (2016).
pubmed: 26763461 pmcid: 4731027 doi: 10.1038/JID.2015.374
Hellgren, L. S. et al. Nuclear-specific accumulation of telomerase reverse transcriptase (TERT) mRNA in TERT promoter mutated follicular thyroid tumours visualised by in situ hybridisation: a possible clinical screening tool? J. Clin. Pathol. https://doi.org/10.1136/jclinpath-2021-207631 (2021).
Morris, L. G. T. et al. The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform. JAMA Oncol. 3, 244–255 (2017).
pubmed: 27442865 pmcid: 5253129 doi: 10.1001/jamaoncol.2016.1790
Nyman, P. E., Buehler, D. & Lambert, P. F. Loss of function of canonical notch signaling drives head and neck carcinogenesis. Clin. Cancer Res. 24, 6308–6318 (2018).
pubmed: 30087145 pmcid: 6295262 doi: 10.1158/1078-0432.CCR-17-3535
Kim, K. T., Kim, B. S. & Kim, J. H. Association between FAT1 mutation and overall survival in patients with human papillomavirus-negative head and neck squamous cell carcinoma. Head Neck 38, E2021–E2029 (2016). Suppl 1.
pubmed: 26876381 pmcid: 5067633 doi: 10.1002/hed.24372
Park, J. Y. et al. Tumor budding in cervical cancer as a prognostic factor and its possible role as an additional intermediate-risk factor. Gynecol. Oncol. 159, 157–163 (2020).
pubmed: 32741542 doi: 10.1016/j.ygyno.2020.07.030
Park, J. Y., Hong, D. G., Chong, G. O. & Park, J. Y. Tumor budding is a valuable diagnostic parameter in prediction of disease progression of endometrial endometrioid carcinoma. Pathol. Oncol. Res. 25, 723–730 (2019).
pubmed: 30604272 doi: 10.1007/s12253-018-0554-x
Huang, B., Cai, J., Xu, X., Guo, S. & Wang, Z. High-grade tumor budding stratifies early-stage cervical cancer with recurrence risk. PLoS One 11, e0166311 (2016).
pubmed: 27861522 pmcid: 5115730 doi: 10.1371/journal.pone.0166311
Zhang, L., Wu, J., Ling, M. T., Zhao, L. & Zhao, K. N. The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol. Cancer 14, 87 (2015).
pubmed: 26022660 pmcid: 4498560 doi: 10.1186/s12943-015-0361-x

Auteurs

Abeer M Salama (AM)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Amir Momeni-Boroujeni (A)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Chad Vanderbilt (C)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Marc Ladanyi (M)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Robert Soslow (R)

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. soslowr@mskcc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH